Vischer with Relief Therapeutics on the issuance of 1 billion new shares
Relief Therapeutics Holding, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, has issued 1,000,000,000 additional registered shares out of the authorised share capital approved by the Annual General Meeting on 18 June 2021.
The new shares were fully subscribed at par value by the Relief’s wholly owned subsidiary, Relief Therapeutics International, and were listed on the SIX Swiss Exchange on 27 July 2021, based on a SIX listing prospectus approved by the Prospectus Office of SIX Exchange Regulation on 26 July 2021.
The new shares are being used in part for payments related to the recently announced AdVita and APR acquisitions, which are part of Relief’s transformation into a fully integrated diversified commercial-stage pharmaceutical company.
Vischer acted as transaction counsel and listing agent. The team consists of Robert Bernet (partner, corporate/m&a, pictured), Peter Kühn (counsel, corporate/m&a) and Christian Schneiter (senior associate, banking & finance).
